Acepodia Announces FDA Clearance of IND Application for ACE1831, an Anti-CD20 Armed Allogeneic gamma delta T-cell Therapy Candidate to Treat Patients with non-Hodgkin's Lymphoma

PR Newswire

Acepodia Presents Preclinical Data on its gamma delta T cell Therapy Candidate ACE1831 at 2022 AACR Meeting

Acepodia Announces Expansion of Board of Directors and Scientific Advisory Board

GlobeNewswire

Acepodia Raises $109 Million Series C Financing to Advance Development of First-in-Class Antibody Cell Effector Therapies

GlobeNewswire

Acepodia Strengthens Board of Directors and Scientific Advisory Board with Key Appointments

GlobeNewswire

Natural Killer Cell Therapy Well Tolerated in Solid Tumors

GeneTherapyLive

Developing Cell Therapies for Solid Tumors and Hematologic Malignancies

GeneTherapyLive

ESMO shifts the HER2 antibody landscape

BioCentury

Acepodia Presents Positive Interim Phase 1 Feasibility Data for Antibody Cell Effector Therapy, ACE1702, in Advanced HER2-Positive Tumors

GlobeNewswire

Acepodia uncorks a very early win for its antibody-natural killer cell conjugates in HER2 tumors

Endpoints News

Acepodia to Present Data from Preclinical and Phase 1 Studies of ACE1702 at the European Society for Medical Oncology (ESMO) 2021 Virtual Congress

GlobeNewswire

Creating Off-the-Shelf Cell Therapies for Cancer

Genetic Engineering & Biotechnology News (GEN)